Publicaciones.

1. Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy. Redox Biol. Apr 2018DOI: 10.1016/j.redox.2017.10.010.

2. Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach. Pharmacol Rev. April 2018DOI: 10.1124/pr.117.014753

3. Transcription factor NFE2L2/NRF2 modulates chaperone-mediated autophagy through the regulation of LAMP2A. Autophagy. Jul 2018. DOI: 10.1080/15548627.2018.1474992

4. Deficiency in the transcription factor NRF2 worsens inflammatory parameters in a mouse model with combined tauopathy and amyloidopathy. Redox Biol. Sep 2018DOI: 10.1016/j.redox.2018.07.006

5. Multi-target-directed ligands for Alzheimer´s disease: discovery of chromone-based monoamine oxidase/cholinesterase inhibitors. Eur. J. Med. Chem. Oct 2018. DOI: 10.1016/j.ejmech.2018.07.056

6. Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discov. Jan 2019DOI: 10.1038/s41573-018-0008-x

7. New flavonoid – N,N-dibenzyl(N-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties. J. Enzyme Inhib. Med. Chem. Mar 2019. DOI10.1080/14756366.2019.1581184  

8. Activators and Inhibitors of NRF2: A Review of Their Potential for Clinical Development. Oxid Med Cell Longev. Jul 2019. DOI: 10.1155/2019/9372182

9. Melatonin-sulforaphane hybrid ITH12674 attenuates glial response in vivo by blocking LPS binding to MD2 and receptor oligomerization. Pharmacological Research. Feb 2020. DOI: 10.1016/j.phrs.2019.104597

10. Tuning melatonin receptor subtype selectivity in oxadiazolone-based analogues: Discovery of QR2 ligands and NRF2 activators with neurogenic properties. Eur. J. Med. Chem. Mar 2020. DOI: 10.1016/j.ejmech.2020.112090